Member Info for MKumar

surprisingly i could buy via HL at 8.9

How would you know it is in auction - just for us to learn

JAdam- I remember you mentioning Immunogenyx collaboration with HEMO. Is Jennsen advac subsidiary of immunogenyx pharma tied up with J and J . Trying to get this right for the HEMO team here , as there are too many players.
Thxs again

Thxs

Mornington and the team here - just followed you from Hemo and brought.
Looks promising here
As new to stocks can you please explain how does Tight spread and wider spread of stock dictate on the SP ( and also the small market cap) Thxs again

Had to buy more at 14 from HL

Intrepid- thxs for realistic valuation .
However not to forget the competition coming up from AVCT and GDR ( despite NCYT having D-pcr quick test technology). There is likely to price/test bargaining going forward which may dent your figures .

Neon - thxs . Hemo turned out to be good buy indeed unlike c4xd. But can you tell us why is c4xd good buy please.
I have looked into this in detail . It has been lingering since last year but has not really made any credible progress with advance molecules, although it seems like it
All the nest to HEMO team tomorrow as it appears to surge further.

Trek, Richken and Olderwiser
Thought provoking posts. Thanks.
Although i was in similar frame of mind with cover related stocks( mind boggling) , it is a good policy to look at the long term changes coming into different businesses and adapt quickly to invest into those stocks. Not sure if you agree I have picked up the following for the long term( any other suggestions would be helpful) AVCT, GDR, HEMO, GGH imho
Still considering BVN

Ofcourse time will tell
B/W
M Kumar

Thxs Mornington.

Sorry silly question- Is it not Aim based.
And also what American Nasdaq companies could buy this out.

That is quite re-assuring Paddy.
As some people are expecting, we may have news a bit early tomorrow
Cheers

olderandwiser I seem to be following you or the other way.
Just brought in here at GDR after gap and hemo. GDR as someone here said is the next Ncyt i think - time will tell as suggested by Bladderman here
Thxs indeed

NCYT will be flying high given the current demand here and in many countries with a very sensitive approved test to its credit .
There may even be a talk of takeover by big pharmas which is not surprising . Sp would be over 7 in 2 weeks i presume
Cheers
M Kumar

Valid points especially value of POC test and mutation issue which i was not aware. GDR appears to be undervalued in comparison.

Techniq and oldandwiser : very good discussion indeed.
I hold shares in NCYT, AVCT and GDR (small part) . Given the PCR dependency of both tests NCYT and GDR , i presume both should have similar specificity/ sensitivity . If so , is it not best to buy in GDR at below £1 than Ncyt which is nearing £4 for better value. I know currently NCYT is in driving seat as it has all necessary approvals and GDR is still not there yet as per my understanding. Your thoughts will be helpful
Cheers

Van V, Danker , Quickdraw , Wilson , troublesome and others here- As you all know we will know more on this soon in few days and no doubt NCYT is in driving seat at the moment and will be more so when they are modifying there current PCR test to fast track the test.

Moving ahead the next challenges we have is appropriate vaccine and treatment. I know some of you have after NCYT , have looked into SNG treatment . There is a new treatment with good success i have posted on HEMO . You can have a loo k if interested.

Looking fwd for next few exciting NYCT news.

Quickdraw and the HEMO members- this is perhaps my first post on this BB.

Having researched HEMO , I believe they have brilliant prospects with their HU-PHECs-( subclass of progenitor cells ) if developed , as I understand they have a patent. These cells apart from fighting the cancer cells they can also fight aggressive infections ie COVID by modifying and augmenting the human immune response. The generation of these fighting cells can of course be from humanised mice. Not sure if you have read the brilliant article with title below : from Israel showing promising 100percent survival rate in serious Covid patients.

I am not sure how to approach the science / admin / CEO team at Haemo to ask wether they are considering this approach to Covid ( although they may be ? considering the same already.)
Any help in this regard from you would take everyone of us forward .

Article: from Pluristem Therapeutics Jerusalem Israel
Israeli COVID-19 treatment with 100% survival rate tested on US patient
After one week, six critically ill patients in Israel survived. Four of them showed improvement in respiratory parameters.

Thxs Van V and the team for your valuable input. Info regarding your statement : NCYT has been assisting Optigene .
I tried to look into this further with my science background . Do you have any info on link between Ncyt and optigene ? This would be helpful as this can be impactful going forward.
On another note i did not get your note : Things are hotting up on WI ; what is WI
cheers

Dougal and team i may be stating the obvious below, but for clarity there is a note below.
Who has been promoting antigen tests , hence approved Novcyt and Roche product
- ODX has antibody detection test. who says that detecting antiodies is of no use as their is no proven value that infection does not occur. The British scientists have now answered this question saying antibody testing as a base will help determine vaccine efficacy, when it comes to hand ? 1 year or so

Adam welcome on this board where I am learning from lot of the knowledgeable people ie Coach, Mercedesman, schlemiel, Oldandwisorand and Paddy to name a few. But there are many more. I note your comment and like you i have recently joined GGP bandwagon . Coach had kindly forwarded me the video below to start your research. All the best

https://twitter.com/The_investmentJ/status/1253385044573519879